Impact of age on bladder cancer management practices: a general population study

References

• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Bladder Cancer [Internet]. [cited 2018 Oct 20]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html.
   Google Scholar
• Fonteyne V, Ost P, Bellmunt J, et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol. 2018;73(1):40–50.
   PubMed Web of Science ®Google Scholar
• Cowppli-Bony A, Uhry Z, Remontet L, et al. Survival of cancer patients in metropolitan France, 1989–2013. Part 1-Solid tumors. Saint-Maurice (France): Institut de veille sanitaire; 2016.
   Google Scholar
• Jensen TK, Jensen NV, Jørgensen SM, et al. Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008–2012. Acta Oncol Stockh Swed. 2016;55(sup1):85–90.
   PubMed Web of Science ®Google Scholar
• CI5 XI - Home [Internet]. [cited 2019 Oct 15]. Available from: http://ci5.iarc.fr/CI5-XI/Default.aspx.
   Google Scholar
• Tyczynski JE, Demaret E, Parkin DM. Standards and Guidelines for Cancer Registration in Europe [Internet]. [cited 2020 Jan 17]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Technical-Publications/Standards-And-Guidelines-For-Cancer-Registration-In-Europe-2003.
   Google Scholar
• Sobin L, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. LH Sobin, MK Gospodarowicz and Ch. Wittekind, editor; New York: Wiley-Liss, Inc; 2009.
   Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–465.
   PubMed Web of Science ®Google Scholar
• Pfister C, Roupret M, Wallerand H, et al. [Recommendations onco-urology 2010: urothelial tumors]. Progres En Urol. 2010;20(Suppl 4):S255–S274.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–4400.
   PubMed Web of Science ®Google Scholar
• Chamie K, Saigal CS, Lai J, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117(23):5392–5401.
   PubMed Web of Science ®Google Scholar
• Noon AP, Albertsen PC, Thomas F, et al. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013;108(7):1534–1540.
   PubMed Web of Science ®Google Scholar
• Patschan O, Holmäng S, Hosseini A, et al. Use of bacillus Calmette-Guérin in stage T1 bladder cancer: long-term observation of a population-based cohort. Scand J Urol. 2015;49(2):127–132.
   PubMed Web of Science ®Google Scholar
• Goossens-Laan CA, Visser O, Wouters M, et al. Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg Oncol. 2010;36(Suppl 1):S100–S107.
   PubMedGoogle Scholar
• Table de Mortalité Des Années 2009–2011 [Internet]. [cited 2018 Oct 29]. Available from: https://www.insee.fr.
   Google Scholar
• Oddens J R, Sylvester R J, Brausi M A, et al. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int. 2016;118(3):423–428.
   PubMedGoogle Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–1639.
   PubMed Web of Science ®Google Scholar
• Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology. 2007;70(1):65–68.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–653.
   PubMed Web of Science ®Google Scholar
• Roupret M, Neuzillet Y, Masson-Lecomte A, et al. Recommandations en onco-urologie 2016–2018 du CCAFU: tumeurs de la vessie. Prog Urol. 2016;27:S67–S91.
   PubMedGoogle Scholar
• Goossens-Laan CA, Leliveld AM, Verhoeven RHA, et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer. 2014;135(4):905–912.
   PubMed Web of Science ®Google Scholar
• Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013;63(5):823–829.
   PubMed Web of Science ®Google Scholar
• Williams SB, Huo J, Chamie K, et al. Underutilization of radical cystectomy among patients diagnosed with clinical stage T2 muscle-invasive bladder cancer. Eur Urol Focus. 2017;3:258–264.
   PubMedGoogle Scholar
• Fischer-Valuck BW, Rao YJ, Rudra S, et al. Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the National Cancer Database. J Urol. 2018;199(2):416–423.
   PubMed Web of Science ®Google Scholar
• Novara G, De Marco V, Aragona M, et al. Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol. 2009;182(3):914–921.
   PubMed Web of Science ®Google Scholar
• Schiffmann J, Gandaglia G, Larcher A, et al. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol. 2014;40:1738–1745.
   PubMed Web of Science ®Google Scholar
• Boustani J, Bertaut A, Galsky MD, et al. Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncol Stockh Swed. 2018;57(4):491–497.
   PubMed Web of Science ®Google Scholar
• Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. Trans Meeting Am Surg Assoc. 2009;127:93–99.
   Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Oncol Pract. 2018;36(22):2326–2347
   Google Scholar
• Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE. 2014;9(12):e115060.
   PubMed Web of Science ®Google Scholar
• Lapôtre-Ledoux B, Plouvier S, Cariou M, et al. Regional estimatie of incidence and mortality from cancers in France, 2007–2016. Hauts-de-France. Saint-Maurice: Santé publique France; 2019.
   Google Scholar
• Spencer BA, McBride RB, Hershman DL, et al. Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 2013;9(2):92–98.
   PubMedGoogle Scholar
• Chamie K, Saigal CS, Lai J, et al. Quality of care in patients with bladder cancer: a case report? Cancer. 2012;118(5):1412–1421.
   PubMed Web of Science ®Google Scholar